FRM
BPMC

Fox Run Management’s Blueprint Medicines BPMC Stock Holding History

Fox Run Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,445
Closed -$1.01M – 883
2025
Q1 		$1.01M Buy
11,445
+1,181
+12% +$115K 0.16% 204
2024
Q4 		$895K Buy
10,264
+7,434
+263% +$681K 0.16% 202
2024
Q3 		$262K Buy
+2,830
New +$281K 0.06% 594
2024
Q2 		– Sell
-4,655
Closed -$442K – 789
2024
Q1 		$442K Buy
4,655
+2,152
+86% +$185K 0.1% 418
2023
Q4 		$231K Buy
+2,503
New +$162K 0.06% 592
2023
Q2 		– Sell
-5,300
Closed -$238K – 702
2023
Q1 		$238K Buy
+5,300
New +$239K 0.08% 470
2022
Q3 		– Sell
-6,082
Closed -$307K – 617
2022
Q2 		$307K Buy
+6,082
New +$356K 0.15% 288
2022
Q1 		– Sell
-2,228
Closed -$239K – 508
2021
Q4 		$239K Buy
+2,228
New +$233K 0.14% 305
2019
Q3 		– Sell
-3,550
Closed -$335K – 375
2019
Q2 		$335K Buy
+3,550
New +$293K 0.22% 185
2018
Q1 		– Sell
-11,067
Closed -$835K – 724
2017
Q4 		$835K Buy
+11,067
New +$779K 0.24% 102

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fox Run Management's BPMC Position: Q2 2025 in Review

Fox Run Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 11,445 shares — an estimated $1.01M sold.

Fox Run Management first reported a position in BPMC in Q4 2017 and held it in 10 quarters. The position peaked at $1.01M in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Fox Run Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Fox Run Management sold 11,445 Blueprint Medicines shares in Q2 2025, an estimated $1.01M.
  • Fox Run Management first reported a position in Blueprint Medicines in Q4 2017 and held it in 10 quarters.
  • Fox Run Management's Blueprint Medicines position peaked at $1.01M in Q1 2025.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.